Corcept Therapeutics Faces Lawsuit Over Misleading Investor Claims on Drug Approval

Corporate Transparency Under Scrutiny at Corcept Therapeutics

Corcept Therapeutics Inc. is currently embroiled in a class action lawsuit stemming from allegations of misleading investors regarding the development of its lead drug candidate, relacorilant. Filed by Hagens Berman, the lawsuit targets the company over claims that it painted an overly optimistic picture of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), despite receiving warnings about the inadequacy of its clinical data. The suit emphasizes that Corcept downplayed FDA concerns while projecting "high confidence" in imminent approval for relacorilant, which is intended to treat hypercortisolism, commonly known as Cushing's syndrome.

The genesis of the allegations traces back to a series of communications from the FDA expressing skepticism about the clinical trials’ ability to demonstrate relacorilant’s effectiveness. Despite these objections, Corcept continued its path toward filing the NDA, leading to claims that they misrepresented the drug's regulatory viability to investors. The situation escalated dramatically on December 31, 2025, when Corcept disclosed the receipt of a Complete Response Letter (CRL) from the FDA, indicating that the agency could not support the medication's benefit-risk profile without further evidence. This announcement led to a staggering plunge in stock price from $70.20 to $34.80 in just one day, marking a significant loss of over $3.6 billion in market capitalization.

The class action suit argues that Corcept and its executives violated the Securities Exchange Act of 1934 by making misleading statements about relacorilant’s regulatory status. With the lawsuit urging affected investors to come forward, the legal proceedings shine a spotlight on the accountability of pharmaceutical companies in their communications regarding drug development and regulatory hurdles. As the pharmaceutical industry grapples with the balance between optimism and transparency, Corcept's predicament underscores the potential ramifications of failing to adhere to regulatory feedback.

In related developments, Robbins LLP has also announced a class action lawsuit on behalf of investors who purchased Corcept stock within the same time frame. Both lawsuits highlight a growing concern among investors about the integrity of corporate communications, particularly in the context of clinical data that shapes drug approval processes. As the litigation unfolds, it could have significant implications for Corcept's future and regulatory practices throughout the pharmaceutical industry.